Supply Chain

Ember LifeSciences and Alfresa, Japan's top pharma wholesaler, form a cold chain alliance as biologics and specialty distribution demand grows.

Peli BioThermal and PAXAFE are partnering to pair cold chain packaging with AI-powered monitoring, signaling where pharma logistics technology is headed next.

Shortages of antibiotics, IV fluids and sterile injectables are hardening as new EU and US rules push pharma to fix the incentives behind them.

Geopolitical instability is pushing life sciences firms to map supply chains beyond suppliers to protect trials and patient access.

How commercial trade groups are shifting from distribution execution to strategic partners shaping market access, launch readiness and commercial performance.

Continuous monitoring, targeted automation and interoperability standards are redefining pharma cold chain custody and cutting temperature excursions.

EVERSANA's Danny Williams on how cell and gene therapies, AI, and direct-to-patient fulfillment are reshaping the pharma 3PL model.

The API Innovation Center's Gerren McHam on China's new supply chain rules, reshoring policy, and where US drug manufacturing goes next.

Specialty drugs, cell and gene therapies, and GLP-1s are reshaping pharma distribution, forcing 3PLs to build for both precision and scale.

ORBIS' Matt Marchetti outlines how pharma companies can define supply chain impact, KPIs, and ROI when transitioning to reusable plastic pallets.

As China tightens supply chain rules, tariff pressure persists, and the FDA's PreCheck Program takes shape, this FAQ breaks down how pharma reshoring stands in 2026.

The FDA selected seven companies, including two CGT manufacturers, for its PreCheck Pilot to accelerate domestic manufacturing approvals and bolster supply chain resilience.

As CGTs scale from clinical to commercial, Cencora's Krystal Haynes discusses the supply chain decisions that determine whether a launch succeeds.

Amber Hussain Siddique explains why that inventory economics, FEFO compliance gaps, and freight cost structures are driving America's persistent drug shortage crisis and what it takes to fix it.

The investment adds 27 temperature-controlled freight facilities across the Americas, Europe, and Asia as demand for biologics distribution infrastructure continues to climb.

As the US and Iran reach a framework agreement to reopen the Strait of Hormuz, Pharmaceutical Commerce breaks down what the deal means for pharmaceutical supply chains.

4flow's Natalia Andreyeva breaks down the persistent planning failures driving AI adoption in pharma supply chains.

By prioritizing solutions such as reusable plastic pallets, pharmaceutical companies can ensure that their high-value innovations are protected by equally innovative packaging.

Generic drug shortages may seem sudden, but they stem from ongoing pressures in manufacturing, pricing, and global supply chains, especially in hospitals.

Pharma supply chains are embracing AI, digital twins, IoT, and DSCSA-driven traceability to improve resilience, visibility, and profitability amid rising global disruptions.

Ben Sharples, LogiPharma event director, examines how life sciences organizations are adapting to AI in the supply chain, with expert testimony from LogiPharma partners.

US pharma supply chains are shifting amid regulation and geopolitics, with BIOSECURE driving less Asia reliance and more complex, distributed networks.

Decision intelligence helps pharma unify small molecule and cell and gene therapy supply chains through AI-driven, automated decision-making.

AI-driven cold chain visibility is only as reliable as the data behind it, exposing gaps between compliance, monitoring, and true product conditions.

Joel Wayment discusses how the cold chain can be more sustainable.